ReviewBioscience reports2019
Role of CyPA in cardiac hypertrophy and remodeling.
Review in Bioscience reports, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.
- Efficacy and safety of coenzyme Q10 in heart failure: a meta-analysis of randomized controlled trials.BMC cardiovascular disorders · 2024Pooled it
- SIRT1 in brain aging: molecular mechanisms and therapeutic potential of pharmacological and natural modulators.Biogerontology · 2026Review
- The Role of the PI3K/Akt/mTOR Pathway in Atherosclerosis: Mechanisms, Therapeutic Potential, and Emerging Targeted Treatments.Current atherosclerosis reports · 2025Review
- Correlation between serum cyclophilin A and acute ST-segment elevation myocardial infarction and its predictive value.Frontiers in cardiovascular medicine · 2025Article
- RhoA/ROCK Pathway Is Upregulated in Experimental Autoimmune Myocarditis and Is Inhibited by Simvastatin at the Stage of Myosin Light Chain Phosphorylation.Biomedicines · 2024Article
- Cellular and extracellular proteomic profiling of paradoxical low-flow low-gradient aortic stenosis myocardium.Frontiers in cardiovascular medicine · 2024Article
- Identification of crucial genes related to heart failure based on GEO database.BMC cardiovascular disorders · 2023Article
- Proteome alterations in erythrocytes with PIEZO1 gain-of-function mutations.Blood advances · 2023Article
- Chronic cerebral hypoperfusion alters the CypA-EMMPRIN-gelatinase pathway: Implications for vascular dementia.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2023Article
- Intervertebral disc degeneration and osteoarthritis: a common molecular disease spectrum.Nature reviews. Rheumatology · 2023Review
- Cyclophilin a represses reactive oxygen species generation and death of hypoxic non-small-cell lung cancer cells by degrading thioredoxin-interacting protein.Cell cycle (Georgetown, Tex.) · 2022Article
- Cyclophilin A contributes to shikonin-induced glioma cell necroptosis and promotion of chromatinolysis.Scientific reports · 2022Article
- Reactive oxygen species contribute to delirium-like behavior by activating CypA/MMP9 signaling and inducing blood-brain barrier impairment in aged mice following anesthesia and surgery.Frontiers in aging neuroscience · 2022Article
- Role of MMP-2 and CD147 in kidney fibrosis.Open life sciences · 2022Review
- Extracellular cyclophilins A and C induce dysfunction of pancreatic microendothelial cells.Frontiers in physiology · 2022Article
- Cyclophilin A causes severe fever with thrombocytopenia syndrome virus-induced cytokine storm by regulating mitogen-activated protein kinase pathway.Frontiers in microbiology · 2022Article
- Peptidyl-prolyl cis-trans isomerase A participates in the selenium transport into the rat brain.Journal of biological inorganic chemistry : JBIC : a publication of the Society of Biological Inorganic Chemistry · 2021Article
- miR-194-5p negatively regulates the proliferation and differentiation of rabbit skeletal muscle satellite cells.Molecular and cellular biochemistry · 2021Article
- Cyclosporin A: A Repurposable Drug in the Treatment of COVID-19?Frontiers in medicine · 2021Review
- Novel Evidence of Acute Kidney Injury in COVID-19.Journal of clinical medicine · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pathological cardiac hypertrophy is a complex process and eventually develops into heart failure, in which the heart responds to various intrinsic or external stress, involving increased interstitial fibrosis, cell death and cardiac dysfunction. Studies have shown that oxidative stress is an important mechanism for this maladaptation. Cyclophilin A (CyPA) is a member of the cyclophilin (CyPs) family. Many cells secrete CyPA to the outside of the cells in response to oxidative stress. CyPA from blood vessels and the heart itself participate in a variety of signaling pathways to regulate the production of reactive oxygen species (ROS) and mediate inflammation, promote cardiomyocyte hypertrophy and proliferation of cardiac fibroblasts, stimulate endothelial injury and vascular smooth muscle hyperplasia, and promote the dissolution of extracellular matrix (ECM) by activating matrix metalloproteinases (MMPs). The events triggered by CyPA cause a decline of diastolic and systolic function and finally lead to the occurrence of heart failure. This article aims to introduce the role and mechanism of CyPA in cardiac hypertrophy and remodeling, and highlights its potential role as a disease biomarker and therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.